Novartis NVA237 Phase III data showed rapid, sustained improvement in lung function and symptom relief over one year in COPD patients
(Thomson Reuters ONE) -
Novartis International AG /
Novartis NVA237 Phase III data showed rapid, sustained improvement in lung
function and symptom relief over one year in COPD patients
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
* GLOW2 study showed NVA237 superior to placebo and similar to open-label
tiotropium in increasing lung function, improving COPD symptoms and reducing
exacerbations[1],[2],[3]
* Results demonstrated that once-daily NVA237 had rapid onset of action at
first dose, sustained 24-hour bronchodilation, and was well tolerated over
52 weeks[1]
* NVA237 submitted for EU approval under proposed brand name Seebri(®)
Breezhaler(®);expect US filing in 2014
* COPD is predicted to be the third leading cause of death by 2020[4]; NVA237
has the potential to provide patients an alternative choice of LAMA therapy
Basel, May 17, 2012 - Results from the pivotal Phase III GLOW2 study
demonstrated that once-daily (QD) 50 mcg NVA237 (glycopyrronium bromide) was
superior to placebo in improving lung function, symptom relief and quality of
life, and reducing exacerbations over a one-year period[1],[2],[3]. The data
will be presented at the 2012 American Thoracic Society (ATS) International
Conference May 18-23, 2012 in San Francisco, CA, USA.
"The GLOW2 results affirm the potential for once-daily NVA237 to help patients
manage their COPD symptoms and improve their quality of life," said Tim Wright,
Head of Development, Novartis Pharmaceuticals. "Novartis is committed to
addressing the unmet needs of COPD patients by providing innovative medicines
and devices, and the results of GLOW2 demonstrate that NVA237 could be the
second innovative product in our COPD portfolio."
GLOW2 met its primary endpoint by demonstrating NVA237 provided superior 24-hour
bronchodilation compared to placebo at 12 weeks measured by mean trough FEV(1)
(97 mL; p<0.001)[1]. At this same time point, trough FEV(1) for open-label (OL)
tiotropium was 83 mL versus placebo (p<0.001)[1]. In addition, NVA237 showed
similar efficacy to OL tiotropium (Spiriva(®) HandiHaler(®)*/18 mcg) in patients
with moderate-to-severe chronic obstructive pulmonary disease (COPD)[1]. NVA237
also demonstrated rapid onset of action (within five minutes at first dose) and
sustained 24-hour bronchodilation over 52 weeks[1].
At Day 1, Week 26 and Week 52 of the GLOW2 study, NVA237 showed significantly
improved lung function (measured by mean trough FEV(1)) compared to placebo (all
p<0.001)[1] and results were similar to those seen with OL tiotropium[1]. At Day
1 and Week 12, 26 and 52, the FEV(1) area under the curve (AUC) for 0-4 hr,
0-12 hr, 12-24 hr, and 0-24 hr for NVA237 was superior to placebo (p<0.05) and
numerically greater than OL tiotropium[1].
The study also demonstrated that NVA237 improved COPD symptoms and quality of
life and reduced exacerbations[2],[3] compared to placebo. NVA237 significantly
reduced breathlessness (measured by the transition dyspnea index or TDI,
p=0.002), improved health-related quality of life (measured by the St George's
Respiratory Questionnaire or SGRQ, p<0.001), reduced use of rescue medication
(p=0.039), and increased the percentage of days with no daytime symptoms
(p<0.05)compared to placebo over 52 weeks[2].
For these symptomatic and quality of life indicators, results were numerically
similar to those observed with OL tiotropium over the same time period[2].
NVA237 also significantly prolonged the time to first exacerbation and
significantly reduced the rate of moderate/severe exacerbations versus placebo
over 52 weeks (p=0.001); these effects were similar to OL tiotropium
(p=0.001)[3].
Throughout the GLOW2 study, NVA237 was well-tolerated with a similar incidence
of adverse events to placebo and OL tiotropium[3]. Serious adverse events were
reported less frequently with NVA237 (12.6%) than with either placebo (15.4%) or
OL tiotropium (15.0%)[3].
GLOW2 was a 52-week double-blind, placebo-controlled, parallel-group study
involving 1,066 patients to assess the efficacy, safety and tolerability of
NVA237 in patients with COPD. Patients were randomized into three treatment arms
receiving either once-daily NVA237 50 mcg or placebo (double-blind), or once-
daily OL tiotropium 18 mcg. They were also permitted to use COPD background
therapy and rescue medication[1],[2],[3].
Phase II clinical trial update
Results have recently been submitted for publication from the NVA237 Phase II
A2208 study. This study comparing once-daily and twice-daily dosing regimens of
NVA237 met its primary endpoint by demonstrating that all treatments (12.5 mcg,
25 mcg and 50 mcg given once or twice daily and 100 mcg once daily) provided
statistically significant bronchodilation over the course of the day (measured
by mean trough FEV(1) at Day 28) in patients with moderate-to-severe COPD
compared to placebo[5].
Differences in lung function (measured by FEV(1) AUC(0-24h))between a single
daily dose of NVA237 and the same total amount given twice daily were small and
not clinically relevant[5]. However once-daily dosing is known to offer the
potential to improve patient adherence[6], an important consideration when
selecting the optimum dosing regimen for a novel bronchodilator. Throughout the
study, NVA237 showed an overall good safety profile and was well tolerated
compared to placebo[5]. The results of A2208 are consistent with previous NVA237
studies and support once-daily dosing of 50 mcg NVA237 in patients with
moderate-to-severe COPD[1],[2],[3],[7],[8].
About NVA237
Seebri(®) Breezhaler(®) (glycopyrronium bromide/NVA237) is an investigational
long-acting muscarinic antagonist (LAMA) developed as a once-daily inhaled
maintenance therapy for the treatment of COPD. NVA237is expected to be one of
three innovative medicines in the Novartis COPD portfolio to be delivered using
the Breezhaler(®) Single Dose Dry Powder Inhaler, along with Onbrez(®)
Breezhaler(®) (indacaterol) and investigational QVA149 (indacaterol 110
mcg/glycopyrronium bromide 50 mcg).
Phase III data from the GLOW 1, 2 and 3 studies demonstrated that NVA237
increased patients' lung function over a 24-hour period compared to placebo,
with a fast onset of action at first dose, as well as improving exercise
endurance[1],[2],[3],[7],[8]. Glycopyrronium bromide was licensed to Novartis in
April 2005 by Vectura and its co-development partner Sosei. It was submitted for
regulatory approval in Europe in Q3 2011 and Japan in Q4 2011, and expected US
filing is the beginning of 2014.
About the Novartis COPD portfolio
Novartis is committed to addressing the unmet medical needs of COPD patients and
improving their quality of life by providing innovative medicines and devices.
Onbrez(®) Breezhaler(® )(indacaterol maleate) is the only COPD treatment to
offer clinically relevant 24-hour bronchodilation combined with a rapid onset of
action at first dose and has shown significant symptomatic improvement
especially on breathlessness[9]. In March 2012, Novartis launched the 75 mcg
once-daily dose in the US under the brand name Arcapta(TM) Neohaler(TM). It is
also available as a 150 mcg once-daily dose in Japan under the brand name
Onbrez(®) Inhalation Capsules.
The first four Novartis QVA149 Phase III studies in the treatment of COPD all
met their primary endpoints[10],[11],[12],[13]. The results of the SHINE,
BRIGHT, ENLIGHTEN and ILLUMINATE studies, which are key components of the IGNITE
program, demonstrate the potential of QVA149 in the treatment of
COPD[10],[11],[12],[13].
About COPD
COPD is a progressive disease associated mainly with tobacco smoking, air
pollution or occupational exposure, which can cause obstruction of airflow in
the lungs resulting in debilitating bouts of breathlessness. It affects an
estimated 210 million people worldwide[14] and is predicted to be the third
leading cause of death by 2020[4]. Although COPD is often thought of as a
disease of the elderly, 50% of patients are estimated to be within the ages of
50 and 65, which means that half of the COPD population are likely to be
impacted at the peak of their earning power and family responsibilities[15].
Disclaimer
The foregoing release contains forward-looking statements that can be identified
by terminology such as "expect," "predicted," "potential," "will," "committed,"
"expected," or similar expressions, or by express or implied discussions
regarding potential marketing submissions or approvals for NVA237 and QVA149, or
regarding the timing of any such submissions or approvals, or regarding
potential future revenues from NVA237, QVA149 and Onbrez Breezhaler. You should
not place undue reliance on these statements. Such forward-looking statements
reflect the current views of management regarding future events, and involve
known and unknown risks, uncertainties and other factors that may cause actual
results with these products to be materially different from any future results,
performance or achievements expressed or implied by such statements. There can
be no guarantee that NVA237 or QVA149 will be submitted or approved for sale in
any market, or that any such submissions or approvals will happen at any
particular time. Nor can there be any guarantee that NVA237, QVA149 or Onbrez
Breezhaler will achieve any particular levels of revenue in the future. In
particular, management's expectations regarding these products could be affected
by, among other things, unexpected regulatory actions or delays or government
regulation generally; unexpected clinical trial results, including unexpected
new clinical data and unexpected additional analysis of existing clinical data;
competition in general; government, industry and general public pricing
pressures; unexpected manufacturing issues; the company's ability to obtain or
maintain patent or other proprietary intellectual property protection; the
impact that the foregoing factors could have on the values attributed to the
Novartis Group's assets and liabilities as recorded in the Group's consolidated
balance sheet, and other risks and factors referred to in Novartis AG's current
Form 20-F on file with the US Securities and Exchange Commission. Should one or
more of these risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results may vary materially from those
anticipated, believed, estimated or expected. Novartis is providing the
information in this press release as of this date and does not undertake any
obligation to update any forward-looking statements contained in this press
release as a result of new information, future events or otherwise.
About Novartis
Novartis provides innovative healthcare solutions that address the evolving
needs of patients and societies. Headquartered in Basel, Switzerland, Novartis
offers a diversified portfolio to best meet these needs: innovative medicines,
eye care, cost-saving generic pharmaceuticals, preventive vaccines and
diagnostic tools, over-the-counter and animal health products. Novartis is the
only global company with leading positions in these areas. In 2011, the Group's
continuing operations achieved net sales of USD 58.6 billion, while
approximately USD 9.6 billion (USD 9.2 billion excluding impairment and
amortization charges) was invested in R&D throughout the Group. Novartis Group
companies employ approximately 124,000 full-time-equivalent associates and
operate in more than 140 countries around the world. For more information,
please visit http://www.novartis.com.
Novartis is on Twitter. Sign up to follow (at)Novartis at
http://twitter.com/novartis.
*Spiriva(®) HandiHaler(®) is a registered trademark by Boehringer Ingelheim
Pharma Gmbh & Co. KG.
References
[1] Kerwin E, et al. NVA237 once daily provides rapid and sustained
bronchodilation in COPD patients, with efficacy similar to tiotropium: The GLOW2
trial. [Abstract A2920: Thematic poster session B41: Monday, 21 May,
2012; 08:15-16:30].
[2] Korenblat P, et al. NVA237 once daily improves dyspnea and health-related
quality of life in patients with COPD: The GLOW2 trial. [Abstract A2254: Poster
discussion session A101: Sunday, 20 May, 2012; 14:00-16:30].
[3] Kerwin E, et al. NVA237 once daily reduces COPD exacerbations with similar
rates to tiotropium: The GLOW2 trial. [Abstract A2255: Poster discussion session
A101: Sunday, 20 May, 2012; 14:00-16:30].
[4] Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global
Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive
Pulmonary Disease. Updated December 2011.
http://www.goldcopd.org/uploads/users/files/GOLD_Report_2011_Feb21.pdf Last
accessed 9 May 2012.
[5] Arievich H, Overend T, Renard D, Gibbs M, Alagappan V, Banerji D. NVA237, an
inhaled long-acting muscarinic antagonist: a dose-ranging study in patients with
COPD. [Respir Res 2012. manuscript in preparation].
[6] Bourbeau J, Bartlett SJ. Patient adherence in COPD. Thorax 2008
Sep;63(9):831-8.
[7] D'Urzo A, et al., Efficacy and safety of once-daily NVA237 in patients with
moderate-to-severe COPD: the GLOW1 trial. Respiratory Research 2011, 12:156 (7
December 2011)
[8] Beeh K, Drollmann A, Di Scala L, Smith R. Once-daily NVA237 improves
exercise endurance from first dose in patients with COPD: the GLOW3 trial. Eur
Respir J 2011;38(Suppl. 55):P4497.
[9] Onbrez(®) Breezhaler(®) (indacaterol) EU Summary of Product Characteristics
May 31, 2011
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/0011
14/human_med_001219.jsp&mid=WC0b01ac058001d124.
[10] QVA149 2313 (ILLUMINATE). Data on file, Novartis Pharma AG.
ClinicalTrials.gov identifier: NCT01315249.
[11] QVA149 A2303 (SHINE). Data on file, Novartis Pharma AG. ClinicalTrials.gov
identifier: NCT01202188.
[12] QVA149 2305 (BRIGHT). Data on file, Novartis Pharma AG. ClinicalTrials.gov
identifier: NCT01294787.
[13] QVA149 A2307 (ENLIGHTEN). Data on file, Novartis Pharma AG.
ClinicalTrials.gov identifier: NCT01120717.
[14] Global Alliance Against Chronic Respiratory Diseases (GARD). Global
surveillance, prevention and control of chronic respiratory diseases: a
comprehensive approach. Available at:
http://www.who.int/gard/publications/GARD%20Book%202007.pdf Last accessed 02
May 2012.
[15] Fletcher MJ et al., COPD Uncovered: An International survey on the impact
of chronic obstructive pulmonary disease (COPD) on a working age population. BMC
Public Health 2011, 11:612.
# # #
Novartis Media Relations
Central media line : +41 61 324 2200
Eric Althoff Christina Clinton
Novartis Global Media Relations Novartis Pharma Communications
+41 61 324 7999 (direct) +41 61 324 8682 (direct)
+41 79 593 4202 (mobile) +41 79 483 4819 (mobile)
eric.althoff(at)novartis.com christina.clinton(at)novartis.com
e-mail: media.relations(at)novartis.com
For Novartis multimedia content, please visit www.thenewsmarket.com/Novartis
For questions about the site or required registration, please contact:
journalisthelp(at)thenewsmarket.com.
Novartis Investor Relations
Central phone: +41 61 324 7944
Susanne Schaffert +41 61 324 7944 North America:
Pierre-Michel Bringer +41 61 324 1065 Helen Boudreau +1 212 830 2404
Thomas Hungerbuehler +41 61 324 8425 Jill Pozarek +1 212 830 2445
Isabella Zinck +41 61 324 7188 Edwin Valeriano +1 212 830 2456
e-mail: investor.relations(at)novartis.com e-mail:
investor.relations(at)novartis.com
Media release (PDF):
http://hugin.info/134323/R/1612966/513596.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Novartis International AG via Thomson Reuters ONE
[HUG#1612966]
Unternehmensinformation / Kurzprofil:
Datum: 17.05.2012 - 07:16 Uhr
Sprache: Deutsch
News-ID 147560
Anzahl Zeichen: 18319
contact information:
Town:
Basel
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 290 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Novartis NVA237 Phase III data showed rapid, sustained improvement in lung function and symptom relief over one year in COPD patients"
steht unter der journalistisch-redaktionellen Verantwortung von
Novartis International AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
